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Introduction {#sec1}
============

The bone marrow microenvironment is uniquely adapted to support hematopoiesis. A complex network of stromal cells in the bone marrow provides key signals that support the proliferation and survival of hematopoietic stem/progenitor cells ([@bib6]). CXCL12-abundant reticular (CAR) cells are perivascular mesenchymal stromal cells that express high levels of CXCL12 and stem cell factor ([@bib29]); they overlap considerably with Leptin-receptor^+^ stromal cells ([@bib40]) and Nestin-GFP^+^ stromal cells in the bone marrow ([@bib19]). CAR cells and NG2^+^ arteriolar pericytes produce cytokines and chemokines that play crucial roles in regulating hematopoietic stem cells (HSCs), including CXCL12 and stem cell factor ([@bib9], [@bib10], [@bib11], [@bib15]). Adipocytes are rare in the bone marrow at birth but increase with aging and after myeloablation ([@bib14], [@bib39]). The presence of adipocytes in the bone marrow negatively correlates with hematopoietic activity ([@bib22]). However, a recent study showed that adipocytes promote hematopoietic recovery following myeloablation through production of stem cell factor ([@bib39]), suggesting a context-specific role for adipocytes in regulating hematopoiesis.

The development and maintenance of mesenchymal stromal cells in the bone marrow is not well characterized. Lineage tracing studies show that *Sp7* (*osterix*)*-cre*-targeted mesenchymal stem/progenitor cells (MSPCs) are present in the perichondrium of the future hindlimb by embryonic day 12.5 (E12.5) ([@bib16], [@bib17]). These fetal MSPCs transiently give rise to all mesenchymal stromal cells in the bone marrow, including osteoblasts, CAR cells, arteriolar pericytes, and adipocytes. However, these stromal cells are gradually replaced during adulthood. Indeed, a distinct *osterix-Cre*-targeted MSPC population is present in neonatal bone marrow and gives rise to long-lived mesenchymal stromal cells ([@bib21]). The signals regulating lineage specification of MSPCs also are not well characterized. Omatsu and colleagues, in two separate studies, showed that *Foxc1* and *Ebf1/Ebf3* contribute to the lineage specification of postnatal MSPCs. Specifically, the Foxc1 transcription factor negative regulates adipocyte differentiation of postnatal MSPCs, while the Ebf1/Ebf3 transcription factors inhibit osteoblast differentiation ([@bib23], [@bib26]).

Transforming growth factor β (TGF-β) is an inflammatory cytokine that also may contribute to MSPC differentiation. Cell culture studies show that TGF-β negatively regulates adipocyte and terminal osteoblast differentiation, while stimulating osteoblast progenitor proliferation ([@bib2], [@bib13], [@bib28]). Studies examining the role of TGF-β signaling in MSPC differentiation *in vivo* are limited. Loss of *Tgfb1* is associated with bone loss and a deficiency of osteoblasts ([@bib30]). *Tgfbr2*, encoding TGF-β receptor 2, is required for TGF-β signaling. Deletion of *Tgfbr2* using *Prx1-Cre*, which is active in early limb bud mesenchyme, results in severe skeletal defects and embryonic lethality ([@bib27]). [@bib32] used an osterix-Cre (*Osx-Cre*) transgene to delete *Tgfbr2* in mesenchymal progenitors. They showed that Osx-Cre, Tgfbr2^fl/fl^ mice have impaired tooth development and reduced mineralization of the mandible due to reduced osteoblast differentiation. In humans, genetic alterations leading to enhanced TGF-β signaling are associated with bone dysplasia in Camurati-Engelmann disease ([@bib31]). Of note, TGF-β regulates HSC quiescence and hematopoietic recovery following myeloablation ([@bib5], [@bib34], [@bib38]). Whether TGF-β signaling in mesenchymal stromal cells contributes to these hematopoietic responses is an open question.

In this study, we characterize the contribution of TGF-β signaling in MSPCs on the development of mesenchymal stromal cells that comprise the bone marrow hematopoietic niche. We show that loss of TGF-β signaling in *Osx-Cre*-targeted fetal MSPCs results in alterations in mesenchymal stromal cells, including marked expansions of CAR cells and adipocytes. Both canonical and noncanonical TGF-β signaling in fetal MSPCs contribute to this phenotype. The resulting alterations in mesenchymal stromal cells are associated with a reduced capacity to support HSCs and a shift in hematopoiesis from lymphopoiesis to myelopoiesis. Together, these data suggest that TGF-β plays a key role in the lineage specification of MSPCs and is required for the emergence of a normal hematopoietic niche during fetal bone marrow development.

Results {#sec2}
=======

Deletion of *Tgfbr2* in *Osx-Cre*-Targeted Mesenchymal Cells Results in a Loss of Mature Osteoblasts {#sec2.1}
----------------------------------------------------------------------------------------------------

To investigate the role of TGF-β in the development and maintenance of bone marrow mesenchymal stromal cells, we deleted *Tgfbr2* in mesenchymal cells using a doxycycline-repressible *Sp7* (osterix)-Cre transgene (*Osx-Cre*) ([@bib17]). Previous studies have shown that *Osx-Cre* targets most mesenchymal stromal cells in the bone marrow, including osteoblasts, adipocytes, pericytes, and CAR cells, but not endothelial cells or hematopoietic cells. *Osx-Cre, Tgfbr2*^*fl/fl*^ male and female mice are severely runted with a body weight less than 30% that of littermate controls ([Figures 1](#fig1){ref-type="fig"}A and 1B). Since most *Osx-Cre, Tgfbr2*^*fl/fl*^ died by 4 weeks of age, we focused our initial analysis of mice at 3 weeks of age, when they appeared healthy.Figure 1Loss of TGF-β Signaling in Mesenchymal Cells Inhibits Osteoblast Maturation(A) *Osx-Cre* Tgfbr2^fl/fl^ mouse and a littermate control mouse.(B) Body weight at 3 weeks of age (n = 5).(C) Micro-computed tomography (micro-CT) data showing bone volume density (BV/TV), bone mineral density (BMD), thickness, and bone area (n = 4).(D) Three-dimensional reconstruction of the micro-CT data in the diaphyseal region of a femur.(E) Representative photomicrographs of the diaphyseal region of *Osx-Cre*, *Ai9*, and *Osx-Cre Tgfbr2*^*fl/fl*^*Ai9* mice showing TdTomato^+^ osteoblasts (OB) lining the bone surface. Counterstaining with DAPI (blue) highlights nuclei.(F) Quantification of endosteal TdTomato^+^ osteoblasts shown as fluorescence intensity per unit of bone surface area (n = 3).(G) Representative photomicrographs showing osteocalcin expression (green).(H) Representative photomicrographs showing osteocalcin expression (red) in femurs from *Tgfbr2*^*fl/fl*^ and *Dmp-1-Cre, Tgfbr2*^*fl/fl*^ mice. Original magnification 20× for all images. Data represent the means ± SEM.

The severe runting in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice suggested impaired bone development. Indeed, micro-computerized tomography (micro-CT) ([@bib4]) analysis of male mice at 3 weeks of age showed significant reductions in the bone volume and bone mineral density in trabecular bone and a decrease in bone thickness and bone area in cortical bone ([Figure 1](#fig1){ref-type="fig"}C). An increase in bone marrow trabecularization also was observed by micro-CT ([Figure 1](#fig1){ref-type="fig"}D) and in histological sections ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Increased trabecularization of the bone marrow can be seen with impaired osteoclast activity. However, the serum level of C-terminal telopeptide of type I collagen, a measure of bone resorption ([@bib3]), was similar in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice and control mice ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Moreover, the number of TRAP^+^ osteoclasts and mRNA expression in the bone marrow of the osteoclast-specific genes, *Acp5* (TRAP) and *Ctsk* (cathepsin K), was comparable with control mice ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Thus, altered osteoclast function is not responsible for the bony defects in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice.

We next examined osteoblasts using histomorphometry of bone sections from *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* mice; these mice express tdTomato in all mesenchymal bone marrow stromal cells, including osteoblasts. The number of tdTomato^+^ endosteal cells in the bone marrow of *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* mice was reduced approximately 4-fold compared with control mice ([Figures 1](#fig1){ref-type="fig"}E and 1F). Consistent with this finding, we also observed a consistent loss of osteocalcin^+^ cells along the endosteum ([Figure 1](#fig1){ref-type="fig"}G).

There is in evidence from cell culture systems that TGF-β signaling in osteoblast progenitors negatively regulates terminal osteoblast differentiation *in vitro*. To examine this *in vivo*, we generated DMP1-Cre, Tgfbr2^fl/fl^ mice. We previously showed that the *DMP1-Cre* transgene targets mature osteoblasts and a subset of CAR cells that likely includes osteoblast progenitors ([@bib36]). *DMP1-Cre, Tgfbr2*^*fl/fl*^ mice are not runted. Moreover, the number of osteocalcin^+^ endosteal osteoblasts is normal ([Figure 1](#fig1){ref-type="fig"}H), suggesting that TGF-β signaling is not required for terminal osteoblast differentiation. Together, these data suggest that TGF-β signaling in a mesenchymal progenitor is required for the efficient development of mature osteoblasts.

Deletion of *Tgfbr2* in *Osx-Cre*-Targeted Mesenchymal Cells Results in a Marked Increase in Bone Marrow Adipocytes {#sec2.2}
-------------------------------------------------------------------------------------------------------------------

Previous studies showed that TGF-β negatively regulates the adipogenic differentiation of mesenchymal cell lines *in vitro* ([@bib8]). We used osmium tetroxide staining with micro-CT to visualize and quantify bone marrow adiposity in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice at 3 weeks of age, when bone marrow adiposity should be minimal ([@bib25]). As expected in control mice, little osmium staining was observed, mainly in the diaphyseal region ([Figure 2](#fig2){ref-type="fig"}A). In contrast, osmium staining was seen throughout the femur, and was increased nearly 80-fold in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice ([Figures 2](#fig2){ref-type="fig"}A and 2B). Consistent with this finding, a marked increase in oil red^+^ cells in the bone marrow of *Osx-Cre, Tgfbr2*^*fl/fl*^ mice also was observed ([Figure 2](#fig2){ref-type="fig"}C). Finally, expression of several genes associated with adipocyte differentiation was significantly increased in the bone marrow of *Osx-Cre, Tgfbr2*^*fl/fl*^ mice, including peroxisome proliferator-activated receptor gamma (*Pparg*) and fatty acid binding protein 4 (*Fabp4*) ([Figure 2](#fig2){ref-type="fig"}D). Collectively, these data show that loss of TGF-β signaling in mesenchymal cells results in a massive increase in bone marrow adiposity.Figure 2Loss of TGF-β Signaling in Mesenchymal Cells Is Associated with Increased Bone Marrow Adiposity(A) Representative micro-CT images showing osmium tetraoxide staining of femurs.(B) Quantification of the osmium tetraoxide signal (n = 5).(C) Representative images of femur sections stained with oil red (red). Original magnification, 10×.(D) RNA expression of the indicated gene relative to β-actin mRNA is shown (n = 5--7). Data represent the means ± SEM.

Deletion of *Tgfbr2* in *Osx-Cre*-Targeted Mesenchymal Cells Results in an Expansion of CAR Cells {#sec2.3}
-------------------------------------------------------------------------------------------------

The signals that regulate the development and maintenance of CAR cells are largely unknown. To assess the impact of TGF-β signaling on CAR cell development and/or maintenance, we generated *Osx-Cre, Tgfbr2*^*fl/fl*^ *Cxcl12*^*gfp*^ mice. As expected, in control mice, CXCL12-GFP-bright perivascular CAR cells were seen throughout the bone marrow ([Figure 3](#fig3){ref-type="fig"}B). In *Osx-Cre, Tgfbr2*^*fl/fl*^ *Cxcl12*^*gfp*^ mice the number of CAR cells was increased. Indeed, by histomorphometry, CAR cell number was increased nearly 7-fold compared with control mice, and GFP expression per CAR cell was increased ([Figures 3](#fig3){ref-type="fig"}B and 3C). Of note, the increase in CAR cells was not due to aberrant CXCL12-GFP expression in adipocytes, since perilipin^+^ adipocytes did not overlap with CXCL12-GFP bright (CAR) cells ([Figure S2](#mmc1){ref-type="supplementary-material"}). Despite the increase in CAR cell number, total bone marrow CXCL12 mRNA expression was significantly decreased, suggesting that CXCL12 mRNA expression per CAR cell is reduced ([Figure 3](#fig3){ref-type="fig"}A). Indeed, despite the increase in CXCL12-GFP expression ([Figure 3](#fig3){ref-type="fig"}B), a trend to decreased CXCL12 mRNA expression (but not other niche factors) was observed in CAR cells sorted from *Osx-Cre, Tgfbr2*^*fl/fl*^ *Cxcl12*^*gfp*^ mice, suggesting that the mechanisms regulating CXCL12-GFP expression are distinct from those regulating endogenous *Cxcl12* expression ([Figure 3](#fig3){ref-type="fig"}D). These data show that loss of TGF-β signaling in mesenchymal cells results in an expansion of CAR cells that have modestly reduced CXCL12 expression.Figure 3Loss of TGF-β Signaling in Mesenchymal Cells Is Associated with an Expansion of CAR Cells(A) Total bone marrow RNA expression of the indicated gene relative to β-actin mRNA is shown (n = 5).(B) Representative images of femur sections showing GFP bright (green) CAR cells. Original magnification 20×.(C) Quantification of CAR cells (n = 4).(D) CXCL12-GFP-bright lineage^−^ cells were sorted from the bone marrow of *Osx-Cre Tgfbr2*^*fl/fl*^*Cxcl12*^*gfp*^ or *Tgfbr2*^*fl/fl*^*Cxcl12*^*gfp*^ mice. RNA expression of the indicated gene relative to β-actin mRNA is shown (n = 4--6). Data represent the means ± SEM.

Deletion of *Tgfbr2* in *Osx-Cre*-Targeted Mesenchymal Cells Is Associated with Altered Hematopoiesis {#sec2.4}
-----------------------------------------------------------------------------------------------------

We next examined the effect of the altered bone marrow microenvironment in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice on hematopoiesis. Compared with controls, *Osx-Cre, Tgfbr2*^*fl/fl*^ mice displayed pancytopenia, with significant decreases in the level of circulating neutrophils, B cells, and T cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Furthermore, bone marrow and spleen cellularity were reduced, even after normalizing to body weight ([Figures 4](#fig4){ref-type="fig"}C--4F). In the bone marrow, a shift from lymphopoiesis to myelopoiesis was observed, characterized by a marked decrease in B cells and a modest increase, on a percentage basis, in myeloid cells and granulocyte/macrophage progenitors, although the absolute number of each hematopoietic cell population was reduced ([Figures 4](#fig4){ref-type="fig"}G, 4H, and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). On a percentage basis, phenotypic HSCs (Kit^+^Sca1^+^lineage^−^CD150^+^CD48^−^ cells) were reduced approximately 2-fold ([Figures 4](#fig4){ref-type="fig"}I and [S3](#mmc1){ref-type="supplementary-material"}D). Due to bone marrow hypocellularity, this resulted in a marked (approximately 10-fold) decrease in the total number of HSCs per femur ([Figure 4](#fig4){ref-type="fig"}J). Even after adjusting for bone marrow volume (total volume − bone volume), the total number of phenotypic HSCs was reduced 2.8-fold in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice ([Figure 4](#fig4){ref-type="fig"}K). Of note, the number of Kit^+^Sca1^+^lineage^−^ cells in the spleen of *Osx-Cre, Tgfbr2*^*fl/fl*^ mice was markedly reduced, arguing against a migration of hematopoietic progenitors from the bone marrow to spleen ([Figures S3](#mmc1){ref-type="supplementary-material"}E--S3H).Figure 4Loss of TGF-β Signaling in Mesenchymal Cells Results in Perturbed Hematopoiesis(A) Peripheral blood counts. WBC, white blood cells; RBC, red blood cells (n = 12).(B) Number of neutrophils, B cells, and T cells in the blood is shown (n = 4).(C--F) Spleen and bone marrow (BM) cellularity (per pelvis and combined lower limbs) (n = 4) (C and E) and after adjusting for body weight (n = 4) (D and F).(G--I) Percentage of the indicated cell type in the bone marrow is shown (n = 5): neutrophils and B cells (G), CMP (common myeloid progenitor), GMP (granulocytes-macrophages progenitors), MEP (myeloid-erythrocytes progenitors) (H), and HSCs (c-kit^+^, lineage^-^, Sca1^+^, CD150^+^, CD48^-^ cells) (I).(J and K) Shown is the absolute number of HSCs per pelvis and combined lower limbs (J) and HSC number after correcting for bone marrow volume (K), which was estimated using micro-CT data as total volume (TV) of femur minus bone volume (BV) (n = 4).(L) Competitive repopulation assays were performed with a 1:1 ratio of donor and wild-type competitor bone marrow. Shown is the percentage of donor (Ly5.2) cells in peripheral blood (n = 15, from three independent experiments).(M) Secondary transplantation was performed after 24 weeks. Shown is the percentage of donor (Ly5.2) cells in the secondary recipients (n = 5). Data represent the means ± SEM.

To assess HSC function, competitive repopulation assays were performed using unpurified bone marrow cells. Despite the decrease in phenotypic HSCs, multilineage long-term repopulating activity of *Osx-Cre, Tgfbr2*^*fl/fl*^ bone marrow was comparable with control mice ([Figure 4](#fig4){ref-type="fig"}L). Moreover, similar donor engraftment was observed following secondary transplantation, suggesting that HSC self-renewal is normal ([Figure 4](#fig4){ref-type="fig"}M). Collectively, these data show that TGF-β signaling in mesenchymal progenitors is required for the development of a normal hematopoietic niche in the bone marrow. Specifically, the altered bone marrow microenvironment in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice is associated with a reduced capacity to support hematopoiesis (in particular, B lymphopoiesis), but with relatively preserved ability to support HSCs under basal conditions.

Postnatal Deletion of *Tgfbr2* in *Osx-Cre*-Targeted Mesenchymal Cells Does Not Result in Impaired Osteoblast or Adipocyte Development {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------

A recent study suggested that mesenchymal stromal cells in the bone marrow are derived from two distinct types of MSPCs ([@bib21]). Primitive or fetal MSPCs, defined as *Osx-Cre*-targeted cells present in fetal bone on E12.5, are responsible for osteoblasts and CAR cells through approximately 3 weeks after birth. Definitive or postnatal MSPCs, defined as *Osx-Cre*-targeted cells present at birth, are responsible for the generation of osteoblasts, CAR, and adipocytes cells in adult mice. To investigate the contribution of TGF-β signaling in the lineage specification of definitive MSPCs, we characterized bone marrow stromal cells in which *Tgfbr2* was deleted postnatally by removing doxycycline at birth. Consistent with a previous study, lineage tracing using *Osx-Cre Tgfbr*^*fl/fl*^ *Ai9* mice suggests that induction of *Osx-Cre* expression on postnatal day 0 (P0) results in efficient targeting of osteoblasts and CAR cells ([Figure 5](#fig5){ref-type="fig"}A) ([@bib21]). *Osx-Cre, Tgfbr2*^*fl/fl*^ mice with postnatal *Tgfbr2* deletion were of normal size. Bone marrow cellularity was comparable ([Figure S4](#mmc1){ref-type="supplementary-material"}D) with control mice, and no increase in bone marrow trabeculae was observed ([Figure 5](#fig5){ref-type="fig"}B). Osteoblast number, as measured by osteocalcin staining, was comparable with control mice ([Figure 5](#fig5){ref-type="fig"}C). Moreover, no increase in perilipin^+^ cells was observed ([Figure 5](#fig5){ref-type="fig"}D). Consistent with the lack of stromal changes, postnatal deletion of *Tgfbr2* had no effect on basal hematopoiesis ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4G). Collectively, these data suggest that TGF-β signaling in definitive MSPCs is dispensable for lineage specification in the early postnatal period.Figure 5TGF-β Signaling in Mesenchymal Cells Postnatally Is Not Required for Osteoblast and Adipocyte DevelopmentDoxycycline was removed at birth (postnatal day) from Osx-Cre *Tgfbr2*^*Δ/Δ*^ or control mice to activate the *Osx-Cre* transgene.(A) Representative image of *Osx-Cre Tgfbr2*^*fl/fl*^*, Ai9* femur sections showing TdTomato (red) and DAPI (blue staining).(B) Representative images of H&E-stained femur sections.(C) Representative images of osteocalcin (green)-stained femur sections.(D) Representative images of femur sections stained for perilipin (green) and DAPI (blue). The far right panel shows a femur section from an *Osx-Cre Tgfbr2*^*fl/fl*^ mouse maintained off doxycycline during development, resulting in constitutive *Osx-Cre* expression. Original magnification 20×.

TGF-β Signaling in Embryonic *Osx-Cre*-Targeted Mesenchymal Progenitors Contributes to Osteoblast Lineage Specification {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------

The lack of major perturbations in mesenchymal stromal cells in the bone marrow of postnatally deleted *Osx-Cre, Tgfbr2*^*fl/fl*^ mice suggested that TGF-β signaling in fetal MSPCs may contribute to lineage specification. To explore this possibility, we examined endochondral bone development in the hind limbs of *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* mice maintained off doxycycline, which results in constitutive *Osx-Cre* expression. We first examined mice at E14.5, at a time just before the development of primary ossification centers. As reported previously, at this time point, the majority of *Osx-Cre*-targeted (tdTomato^+^) cells localize to the perichondrium that surrounds hypertrophic chondrocytes at the site of future long bones ([@bib17]) ([Figures 6](#fig6){ref-type="fig"}A and 6B). Maes et al. showed that these osterix-expressing cells invade the cartilage and give rise to trabecular osteoblasts and other bone marrow stromal cells. The number and perichondrial localization of *Osx-Cre*-targeted cells in *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* mice was similar to control mice ([Figure 6](#fig6){ref-type="fig"}B). Strikingly, even at this early stage of bone development, a marked increase in perilipin^+^ cells was observed in the bone collar of the developing hindlimb at E14.5 of *Osx-Cre, Tgfbr2*^*fl/fl*^ mice ([Figure 6](#fig6){ref-type="fig"}C). The increase in perilipin^+^ cells in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice on E16.5 was even more striking, with most Osx-Cre-targeted cells also staining for perilipin ([Figures 6](#fig6){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}D). However, *Osx-Cre, Tgfbr2*^*fl/fl*^ chondrocyte number and distribution were similar to littermate controls ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B).Figure 6TGF-β Signaling Is Required for the Lineage Specification of Fetal Mesenchymal Stem/Progenitor Cells(A) Schematic of bone development at E14.5 showing the perichondrial "bone collar" (red) surrounding hypertrophic chondrocytes (light blue). The region imaged in (B) is shown.(B) Representative images of E14.5 hindlimb sections showing TdTomato^+^ cells comprising the perichondrial collar. Original magnification 20×.(C and D) Representative images of E14.5 (C) or E16.5 (D) hindlimb sections from an *Osx-Cre Ai9* (i) or *Osx-Cre Tgfbr2*^*fl/fl*^*Ai9* (ii) mouse stained for perilipin (green), CD31 to highlight the vasculature (white), and DAPI (blue).(E and F) Microarray was performed on *Osx-Cre*-targeted (tdTomato^+^) cells from E16.5 hindlimbs (n = 4--6). Gene set enrichment analysis identified increased adipogenesis in cells from *Osx-Cre Tgfbr2*^*fl/fl*^*Ai9* mice (E). Heatmap of selected adipocyte marker genes (F).

To further assess the impact of TGF-β signaling on fetal MSPC lineage specification, we sorted *Osx-Cre*-targeted (TdTomato^+^) cells from the hind limbs of E16.5 *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* or *Osx-Cre Ai9* mice and performed RNA expression profiling. Gene set enrichment analysis yielded multiple hits for increased adipogenesis ([Figure 6](#fig6){ref-type="fig"}E). Indeed, expression of key regulators or markers of adipogenesis, including *Pparγ*, *Plin2* (perilipin), *Cd36*, *Fabp4*, and *Adipoq* (adiponectin) was increased in *Osx-Cre, Tgfbr2*^*fl/fl*^ *Ai9* cells ([Figure 6](#fig6){ref-type="fig"}F). Interestingly, no alteration in expression of osteoblast lineage genes was observed ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Together, these data suggest that TGF-β signaling plays a key role in lineage specification of fetal MSCPs, suppressing adipogenesis while supporting osteoblast development.

Noncanonical and Canonical TGF-β Negatively Regulates Adipogenesis {#sec2.7}
------------------------------------------------------------------

Canonical TGF-β signaling depends on SMAD4 ([@bib18]). To investigate whether MSPC lineage specification by TGF-β depends on SMAD4, we generated *Osx-Cre, Smad4*^*flfl*^ mice. Of note, canonical signaling by TGF-β and other TGF family members, such as bone morphogen proteins and activins, are disrupted in these mice ([@bib20]). *Osx-Cre, Smad4*^*fl/fl*^ mice are runted to a similar degree as *Osx-Cre, Tgfbr2*^*fl/fl*^ mice. Also similar to *Osx-Cre, Tgfbr2*^*fl/fl*^ mice, *Osx-Cre Smad4*^*fl/fl*^ mice displayed increased trabecularization of their bone marrow cavity and a loss of mature osteoblasts ([Figures 7](#fig7){ref-type="fig"}A and 7Β). However, the magnitude of the increase in bone marrow adiposity was reduced in *Osx-Cre Smad4*^*fl/fl*^ mice compared with *Osx-Cre, Tgfbr2*^*fl/fl*^ mice as assessed by perilipin and oil red staining ([Figures 7](#fig7){ref-type="fig"}C, 7D, and [S6](#mmc1){ref-type="supplementary-material"}).Figure 7TGF-β Regulates Adipogenesis through Canonical and Noncanonical Pathways(A) Representative images of H&E-stained femur sections. Original magnification 10×.(B) Representative images of osteocalcin (red)-stained femur sections.(C) Representative images of perilipin (green)-stained femur sections. DAPI (blue). Original magnification 40×.(D) Shown is the number of perilipin^+^ cells per high-powered field (n = 4).(E) Experimental schema. CFU-A represents culture conditions that favor adipocyte development. iMAPK, MAPK inhibitor.(F) Representative images of wild-type mesenchymal stromal cell cultures stained with oil red (purple/red staining) to identify adipocytes (black arrowheads). "Media" refers to cultures not induced to adipocyte differentiation.(G) Wild-type mesenchymal stromal cells were stimulated with TGF-β overnight and cell lysates immunoblotted for total and phosphorylated PPARγ. Each lane represents an independent culture; all samples were run on the same gel.(H) Densitometry data for phosphorylated PPARγ normalized to total PPARγ (n = 3). Data represent the means ± SEM.

These data suggested that noncanonical signaling contributes to the suppressive effect of TGF-β on adipogenesis. To test this hypothesis, we generated cultures of mesenchymal stromal cells from wild-type neonatal bone marrow ([Figure 7](#fig7){ref-type="fig"}E). Adipogenesis was induced by the inclusion of dexamethasone, insulin, and indomethacin in the culture media (CFU-A). As expected, in wild-type cultures, the addition of TGF-β potently suppressed adipocyte formation, as measured by oil red staining ([Figure 7](#fig7){ref-type="fig"}F). Of note, similar results were observed with mesenchymal stromal cells derived from E16.5 hindlimbs ([Figure S7](#mmc1){ref-type="supplementary-material"}). Noncanonical TGF-β signaling includes activation of mitogen-activated protein kinase (MAPK) ([@bib37]). To assess the role of MAPK activation on the suppression of adipogenesis by TGF-β, we pharmacologically inhibited MAPK activation in wild-type MSPC cultures. Inhibition of MAPK alone did not suppress adipocyte formation. However, it completely blocked the suppressive effect of TGF-β on adipogenesis ([Figure 7](#fig7){ref-type="fig"}F). Previous studies showed that phosphorylation of serine 82 of PPARγ by MAPK decreases its transcriptional activity ([@bib7]). Since PPARγ is a master regulator of adipogenesis, we assessed the ability of TGF-β to induce PPARγ phosphorylation. Indeed, the addition of TGF-β to the MSPC cultures resulted in reproducible PPARγ phosphorylation ([Figures 7](#fig7){ref-type="fig"}H and 7E). Collectively, these data suggest that TGF-β suppresses adipocyte specification of MSPCs, in part, in an MAPK-dependent fashion through phosphorylation of PPARγ.

Discussion {#sec3}
==========

In this study, we show that TGF-β signaling plays a key role in the lineage specification of MSPCs during fetal bone development. Specifically, loss of TGF-β signaling in *Osx-Cre*-targeted MSPCs at sites of developing bones results in a marked expansion of adipocytes and CAR cells, while mature osteoblasts are reduced. In contrast, deletion of *Tgfbr2* in *Osx-Cre*-targeted MSPCs at birth has no apparent effect on mesenchymal cell lineage commitment. These data suggest that TGF-β signaling in fetal, but not adult, MSPCs, plays a key role in lineage specification. Of note, the ability of TGF-β to suppress adipogenesis in cultures MPSCs from fetal or postnatal day 1--4 bone marrow was similar, suggesting that non-cell intrinsic mechanisms may be responsible for the differential reliance on TGF-β *in vivo*. Whether differences in the level of active TGF-β or the presence of other TGF-β family members in the local microenvironment account for this difference will require further study. Likewise, further study is needed to define the importance of TGF-β signaling on the response of bone marrow resident MSPCs to aging or stressors, such as bone fracture or myeloablative therapy.

Previous studies have yielded mixed results with respect to the role of TGF-β signaling in the regulation of osteoblasts ([@bib2], [@bib33]). Cell culture studies suggested that TGF-β negatively regulates terminal osteoblast differentiation ([@bib2]). Consistent with these data, abrogation of TGF-β signaling in osteoblasts and osteoblast precursors in *Ocn-Cre Tgfbr2*^*fl/fl*^ mice is associated with an increased bone mass ([@bib24]). However, our data show that constitutive deletion of *Tgfbr2* in MSPCs is associated with reduced bone mass and a loss of osteoblasts. Moreover, we observed no change in osteoblast number in *DMP1-Cre Tgfbr2*^*fl/fl*^ mice, in which TGF-β signaling is abrogated in mature osteoblasts and preosteoblasts ([@bib36]). Although we did not directly measure bone metabolism, these data suggest that TGF-β signaling is dispensable for terminal osteoblast differentiation. Of note, our data are consistent with a previous report showing that global loss of *Tgfb1* is associated with bone loss ([@bib30]). Reconciling these disparate results is uncertain, but may be related to stage-specific effects of TGF-β signaling on osteoblast development.

The mechanisms regulating MSPC differentiation into adipocytes are not well understood. Our data show that TGF-β is a potent negative signal regulating adipocyte specification in the developing bone marrow. Indeed, in the absence of TGF-β signaling in fetal MSPCs, there is a striking increase in bone marrow adiposity. This phenotype is similar to that reported for mice whereby the transcription factor *Foxc1* is deleted in mesenchymal progenitors ([@bib23]). However, we observed no difference in *Foxc1* mRNA expression in sorted fetal MSPCs from *Osx-Cre, Tgfbr2*^*fl/fl*^ versus control mice (gene expression normalized signal: 52.0 ± 6.0 versus 60.3 ± 7.3, respectively; p = 0.41). Previous studies have suggested that TGF-β inhibits adipogenesis in cell lines in an SMAD-dependent fashion through repression of CCAAAT/enhancer binding protein transcriptional activity, which ultimately results in reduced PPARγ mRNA expression ([@bib2]). Consistent with this observation, we observed increased PPARγ mRNA in sorted fetal MSPCs from Osx-Cre, Tgfbr2^fl/fl^ mice. Furthermore, our data show that SMAD-independent signaling also contributes to the inhibition of adipogenesis by TGF-β. Consistent with previous studies, we show that activation of MAPK by TGF-β results in phosphorylation of serine-82 of PPARγ, which is known to inhibit its transcriptional activity ([@bib1], [@bib7], [@bib12]). Indeed, we show that inhibition of MAPK abrogates the ability of TGF-β to suppress adipocyte differentiation of culture primary MSPCs. Together, these data suggest that both canonical and noncanonical TGF-β signaling contribute to the lineage specification of MSPC in the bone marrow.

Our data suggest that TGF-β signaling plays an important role in establishing hematopoietic niches in the bone marrow. Significant alterations in three important stromal components of the niche are altered in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice. CAR cells, a key component of the stem cell niche, are increased approximately 5-fold. However, despite the increase in CAR cells, total bone marrow expression of CXCL12 was modestly decreased. This can be explained, in part, by reduced CXCL12 mRNA expression in CAR cells, although loss of CXCL12 expression from other stromal cell populations, such as osteoblasts, likely contributes to the overall decrease in bone marrow CXCL12. Although phenotypic HSCs are modestly reduced, functional HSCs, as measured by long-term repopulating assays, were normal after adjusting for bone marrow cellularity. Consistent with previous studies suggesting that osteoblasts are a key component of the lymphoid niche in the bone marrow ([@bib9], [@bib35]), a prominent shift from lymphopoiesis to myelopoiesis was observed in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice. Increased bone marrow adiposity is associated with reduced hematopoietic activity. Consistent with this observation, we observed reduced bone marrow cellularity in *Osx-Cre, Tgfbr2*^*fl/fl*^ mice (even after adjusting for their reduced size). A recent study showed that adipocytes are induced following myeloablation and contribute to hematopoietic recovery ([@bib39]). TGF-β also is induced, raising the possibility that increased TGF-β signaling may suppress adipocyte expansion following myeloablation and limit hematopoietic recovery.

In summary, our data suggest that TGF-β plays a key role in the lineage specification of fetal MSPCs during development and is required for the proper development of fetal hematopoietic niches in the bone marrow. The contribution of TGF-β signaling in MSPCs to the stromal and hematopoietic response to different stressors is an active area of investigation.

Experimental Procedures {#sec4}
=======================

Experimental methods are briefly summarized. A detailed description is provided in [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Mice {#sec4.1}
----

All mice were backcrossed onto a C57Bl/6 background and were maintained under standard pathogen-free conditions according to methods approved by the Washington University Animal Studies Committee. All experiments were done using 3-week-old mice unless stated otherwise. An equal number of male and female mice were used.

Cell Sorting {#sec4.2}
------------

Hindlimbs from E16.5 mice were homogenized and digested with collagenase. TdTomato^+^ CXC12-GFP-bright, CD45^−^ CDllb^−^, Gr1^−^, B220^−^ cells were sorted using a Sony iCyt Synergy SY3200 cell sorter.

Micro-CT and Osmium Staining {#sec4.3}
----------------------------

Hindlimbs were incubated overnight at 4°C in 10% neutral buffered formalin and then embedded in 2% agarose. For osmium staining, hindlimbs were fixed with 10% neutral-buffer formalin, decalcified in 14% EDTA (pH 7.4), for 2 weeks, and then incubated in 1% osmium tetroxide for 48 h at room temperature. Processed tissues were scanned at 10-μm voxel resolution using a Scanco μCT 40.

Immunostaining of Bone Sections {#sec4.4}
-------------------------------

Mouse hindlimbs were fixed in 4% paraformaldehyde, decalcified, incubated in 30% sucrose, and then embedded in optimal cutting temperature compound. Twelve-micron tissue sections were incubated with the Avidin/Biotin Blocking Kit (Vector Laboratories) and then incubated overnight with the indicated primary antibodies overnight at 4°C. Images were acquired using an LSM 700 confocal microscope (Carl Zeiss Microscopy) and processed using Volocity software (PerkinElmer).

Mesenchymal Stromal Cell Culture {#sec4.5}
--------------------------------

Hindlimbs bones from mice at E16.5 or P1--4 were mechanically disrupted and cultured overnight. Nonadherent cells were removed after 24 h. To induce adipogenesis, dexamethasone (100 nM), insulin (5 μg/mL), and indomethacin (50 mM) were added to the culture media for 5 days. Where indicated, recombinant murine TGF-β (20 ng/mL) and/or a combination of two MAPK inhibitors, U0126 (20 μM) and PD98059 (20 μM), were included in the cultures 24 h before inducing adipogenesis.

Statistical Analysis {#sec4.6}
--------------------

Significance was determined using PRISM software (GraphPad), except in the case of the RNA expression profiling data, which was analyzed using the Affymetrix Transcriptome Analysis Console. For single-parameter analysis, unpaired t tests were used to assess statistical significance. For multiple parameter data, statistical significance was calculated using one-way or two-way ANOVA. The number of replicates (n) refers to individual mice, unless otherwise indicated. p values \<0.05 were considered significant.
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